Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Basi farmacologiche della medicina : farmacologia generale, farmacologia speciale / Francesco Rossi, V. Calderaro... [et al.]
| Basi farmacologiche della medicina : farmacologia generale, farmacologia speciale / Francesco Rossi, V. Calderaro... [et al.] |
| Pubbl/distr/stampa | Torino : Utet, c1997 |
| Descrizione fisica | XIV, 783 p. : ill. ; 28 cm |
| Disciplina | 615.2 |
| Altri autori (Persone) |
Rossi, Francesco
Calderaro, Vincenzo |
| Collana | Professione medico. Le basi |
| Soggetto non controllato | farmacologia |
| ISBN | 88-02-05167-4 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | ita |
| Record Nr. | UNIPARTHENOPE-000005716 |
| Torino : Utet, c1997 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Parthenope | ||
| ||
Bioinorganic medicinal chemistry [[electronic resource] /] / edited by Enzo Alessio
| Bioinorganic medicinal chemistry [[electronic resource] /] / edited by Enzo Alessio |
| Pubbl/distr/stampa | Weinheim, Germany, : bWiley-VCH, c2011 |
| Descrizione fisica | 1 online resource (442 p.) |
| Disciplina | 615.2 |
| Altri autori (Persone) | AlessioE (Enzo) |
| Soggetto topico |
Pharmaceutical chemistry
Bioinorganic chemistry |
| Soggetto genere / forma | Electronic books. |
| ISBN |
3-527-63312-X
1-283-37048-4 9786613370488 3-527-63311-1 3-527-63310-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Bioinorganic Medicinal Chemistry; Contents; List of Contributors; 1: Medicinal Inorganic Chemistry: State of the Art, New Trends, and a Vision of the Future: Nicola J. Farrer and Peter J. Sadler; 1.1: Introduction; 1.1.1: Metals in the Body: Essential Elements and Diseases of Metabolism; 1.1.2: Metals as Therapeutic Agents; 1.2: Antimicrobial Agents; 1.3: Antiviral Agents; 1.4: Systemic and Metabolic Diseases Including Inflammation; 1.4.1: Diabetes and Obesity; 1.4.2: Metal Homeostasis and Related Diseases; 1.5: Metal Chelating Agents; 1.6: Antiarthritic Drugs and Inflammation
1.7: Bipolar Disorder1.8: Anticancer Agents; 1.8.1: PtII Cytotoxic Agents; 1.8.2: PtIV Prodrugs; 1.8.3: Photoactivatable PtIV Complexes; 1.8.4: Ruthenium; 1.8.4.1: Interaction with Plasma Proteins; 1.8.4.2: Ruthenium Arenes; 1.8.5: Osmium; 1.8.6: Titanium; 1.8.7: Gold; 1.8.8: Tin; 1.8.9: Gallium; 1.8.10: Arsenic; 1.8.11: Copper; 1.8.12: Zinc; 1.8.13: Bismuth; 1.8.14: Molybdenum; 1.8.15: Photosensitizers: Porphyrins; 1.9: Small Molecule Delivery and Control; 1.9.1: Nitric Oxide (NO); 1.9.2: Carbon Monoxide (CO); 1.10: Diagnostic Agents; 1.11: Veterinary Medicinal Inorganic Chemistry 1.12: Conclusions and Vision2: Targeting Strategies for Metal-Based Therapeutics: Julia F. Norman and Trevor W. Hambley; 2.1: Introduction; 2.2: Physiological Targeting; 2.2.1: Antitumor Drugs Targeting Tumor Hypoxia; 2.2.2: Antitumor Drugs Targeting Vascular Structure; 2.2.3: Antitumor Drugs Targeting Tumor pH; 2.2.4: Light Activated Prodrugs; 2.3: Molecular Targeting; 2.3.1: Protein and Peptide Targeting; 2.3.1.1: Protein Receptor Binding; 2.3.2: Peptide Tethering; 2.3.2.1: Directing Effects; 2.3.3: Selective Activation; 2.3.4: DNA Targeting; 2.3.4.1: Duplex DNA Sequence Selectivity 2.3.4.2: Telomeric Targeting2.4: Immunological Targeting; 2.4.1: Antigen Targeting; 2.4.2: Antibody Tethering; 2.5: Concluding Remarks; 3: Current Status and Mechanism of Action of Platinum-Based Anticancer Drugs: Shanta Dhar and Stephen J. Lippard; 3.1: Introduction; 3.1.1: Platinum Chemotherapy and Cancer; 3.1.2: Palette of Current Platinum Chemotherapeutic Drugs; 3.1.3: Early History of Cisplatin and Approved Platinum Drugs for the Clinic; 3.2: Mechanism of Action of Cisplatin; 3.2.1: Cisplatin Accumulation; 3.2.2: Cisplatin Activation; 3.2.2.1: Binding to DNA Targets 3.2.2.2: Binding to Non-DNA Targets3.2.3: Cellular Processing of Platinum-DNA Adducts; 3.2.3.1: Cytotoxicity Associated with High Mobility Group (HMG) Proteins; 3.2.3.2: Cytotoxicity Associated with Non-HMG Proteins; 3.3: Limitations of Current Platinum-Based Compounds: New Strategies; 3.4: Novel Concepts in the Development of Platinum Antitumor Drugs; 3.4.1: Functionalized Single-Walled Carbon Nanotubes (SWNTs) as Vehicles for Delivery of Pt(IV)-Prodrugs; 3.4.2: Targeted Nanoparticles for Delivery of Cisplatin for Prostate Cancer 3.4.3: Gold Nanoparticles as Delivery Vehicles for Platinum Compounds |
| Record Nr. | UNINA-9910133642203321 |
| Weinheim, Germany, : bWiley-VCH, c2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Bioinorganic medicinal chemistry [[electronic resource] /] / edited by Enzo Alessio
| Bioinorganic medicinal chemistry [[electronic resource] /] / edited by Enzo Alessio |
| Pubbl/distr/stampa | Weinheim, Germany, : Wiley-VCH, c2011 |
| Descrizione fisica | 1 online resource (442 p.) |
| Disciplina | 615.2 |
| Altri autori (Persone) | AlessioE (Enzo) |
| Soggetto topico |
Pharmaceutical chemistry
Bioinorganic chemistry |
| ISBN |
3-527-63312-X
1-283-37048-4 9786613370488 3-527-63311-1 3-527-63310-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Bioinorganic Medicinal Chemistry; Contents; List of Contributors; 1: Medicinal Inorganic Chemistry: State of the Art, New Trends, and a Vision of the Future: Nicola J. Farrer and Peter J. Sadler; 1.1: Introduction; 1.1.1: Metals in the Body: Essential Elements and Diseases of Metabolism; 1.1.2: Metals as Therapeutic Agents; 1.2: Antimicrobial Agents; 1.3: Antiviral Agents; 1.4: Systemic and Metabolic Diseases Including Inflammation; 1.4.1: Diabetes and Obesity; 1.4.2: Metal Homeostasis and Related Diseases; 1.5: Metal Chelating Agents; 1.6: Antiarthritic Drugs and Inflammation
1.7: Bipolar Disorder1.8: Anticancer Agents; 1.8.1: PtII Cytotoxic Agents; 1.8.2: PtIV Prodrugs; 1.8.3: Photoactivatable PtIV Complexes; 1.8.4: Ruthenium; 1.8.4.1: Interaction with Plasma Proteins; 1.8.4.2: Ruthenium Arenes; 1.8.5: Osmium; 1.8.6: Titanium; 1.8.7: Gold; 1.8.8: Tin; 1.8.9: Gallium; 1.8.10: Arsenic; 1.8.11: Copper; 1.8.12: Zinc; 1.8.13: Bismuth; 1.8.14: Molybdenum; 1.8.15: Photosensitizers: Porphyrins; 1.9: Small Molecule Delivery and Control; 1.9.1: Nitric Oxide (NO); 1.9.2: Carbon Monoxide (CO); 1.10: Diagnostic Agents; 1.11: Veterinary Medicinal Inorganic Chemistry 1.12: Conclusions and Vision2: Targeting Strategies for Metal-Based Therapeutics: Julia F. Norman and Trevor W. Hambley; 2.1: Introduction; 2.2: Physiological Targeting; 2.2.1: Antitumor Drugs Targeting Tumor Hypoxia; 2.2.2: Antitumor Drugs Targeting Vascular Structure; 2.2.3: Antitumor Drugs Targeting Tumor pH; 2.2.4: Light Activated Prodrugs; 2.3: Molecular Targeting; 2.3.1: Protein and Peptide Targeting; 2.3.1.1: Protein Receptor Binding; 2.3.2: Peptide Tethering; 2.3.2.1: Directing Effects; 2.3.3: Selective Activation; 2.3.4: DNA Targeting; 2.3.4.1: Duplex DNA Sequence Selectivity 2.3.4.2: Telomeric Targeting2.4: Immunological Targeting; 2.4.1: Antigen Targeting; 2.4.2: Antibody Tethering; 2.5: Concluding Remarks; 3: Current Status and Mechanism of Action of Platinum-Based Anticancer Drugs: Shanta Dhar and Stephen J. Lippard; 3.1: Introduction; 3.1.1: Platinum Chemotherapy and Cancer; 3.1.2: Palette of Current Platinum Chemotherapeutic Drugs; 3.1.3: Early History of Cisplatin and Approved Platinum Drugs for the Clinic; 3.2: Mechanism of Action of Cisplatin; 3.2.1: Cisplatin Accumulation; 3.2.2: Cisplatin Activation; 3.2.2.1: Binding to DNA Targets 3.2.2.2: Binding to Non-DNA Targets3.2.3: Cellular Processing of Platinum-DNA Adducts; 3.2.3.1: Cytotoxicity Associated with High Mobility Group (HMG) Proteins; 3.2.3.2: Cytotoxicity Associated with Non-HMG Proteins; 3.3: Limitations of Current Platinum-Based Compounds: New Strategies; 3.4: Novel Concepts in the Development of Platinum Antitumor Drugs; 3.4.1: Functionalized Single-Walled Carbon Nanotubes (SWNTs) as Vehicles for Delivery of Pt(IV)-Prodrugs; 3.4.2: Targeted Nanoparticles for Delivery of Cisplatin for Prostate Cancer 3.4.3: Gold Nanoparticles as Delivery Vehicles for Platinum Compounds |
| Record Nr. | UNISA-996207922203316 |
| Weinheim, Germany, : Wiley-VCH, c2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Bioinorganic medicinal chemistry / / edited by Enzo Alessio
| Bioinorganic medicinal chemistry / / edited by Enzo Alessio |
| Pubbl/distr/stampa | Weinheim, Germany, : bWiley-VCH, c2011 |
| Descrizione fisica | 1 online resource (442 p.) |
| Disciplina | 615.2 |
| Altri autori (Persone) | AlessioE (Enzo) |
| Soggetto topico |
Pharmaceutical chemistry
Bioinorganic chemistry |
| ISBN |
9786613370488
9783527633128 352763312X 9781283370486 1283370484 9783527633111 3527633111 9783527633104 3527633103 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Bioinorganic Medicinal Chemistry; Contents; List of Contributors; 1: Medicinal Inorganic Chemistry: State of the Art, New Trends, and a Vision of the Future: Nicola J. Farrer and Peter J. Sadler; 1.1: Introduction; 1.1.1: Metals in the Body: Essential Elements and Diseases of Metabolism; 1.1.2: Metals as Therapeutic Agents; 1.2: Antimicrobial Agents; 1.3: Antiviral Agents; 1.4: Systemic and Metabolic Diseases Including Inflammation; 1.4.1: Diabetes and Obesity; 1.4.2: Metal Homeostasis and Related Diseases; 1.5: Metal Chelating Agents; 1.6: Antiarthritic Drugs and Inflammation
1.7: Bipolar Disorder1.8: Anticancer Agents; 1.8.1: PtII Cytotoxic Agents; 1.8.2: PtIV Prodrugs; 1.8.3: Photoactivatable PtIV Complexes; 1.8.4: Ruthenium; 1.8.4.1: Interaction with Plasma Proteins; 1.8.4.2: Ruthenium Arenes; 1.8.5: Osmium; 1.8.6: Titanium; 1.8.7: Gold; 1.8.8: Tin; 1.8.9: Gallium; 1.8.10: Arsenic; 1.8.11: Copper; 1.8.12: Zinc; 1.8.13: Bismuth; 1.8.14: Molybdenum; 1.8.15: Photosensitizers: Porphyrins; 1.9: Small Molecule Delivery and Control; 1.9.1: Nitric Oxide (NO); 1.9.2: Carbon Monoxide (CO); 1.10: Diagnostic Agents; 1.11: Veterinary Medicinal Inorganic Chemistry 1.12: Conclusions and Vision2: Targeting Strategies for Metal-Based Therapeutics: Julia F. Norman and Trevor W. Hambley; 2.1: Introduction; 2.2: Physiological Targeting; 2.2.1: Antitumor Drugs Targeting Tumor Hypoxia; 2.2.2: Antitumor Drugs Targeting Vascular Structure; 2.2.3: Antitumor Drugs Targeting Tumor pH; 2.2.4: Light Activated Prodrugs; 2.3: Molecular Targeting; 2.3.1: Protein and Peptide Targeting; 2.3.1.1: Protein Receptor Binding; 2.3.2: Peptide Tethering; 2.3.2.1: Directing Effects; 2.3.3: Selective Activation; 2.3.4: DNA Targeting; 2.3.4.1: Duplex DNA Sequence Selectivity 2.3.4.2: Telomeric Targeting2.4: Immunological Targeting; 2.4.1: Antigen Targeting; 2.4.2: Antibody Tethering; 2.5: Concluding Remarks; 3: Current Status and Mechanism of Action of Platinum-Based Anticancer Drugs: Shanta Dhar and Stephen J. Lippard; 3.1: Introduction; 3.1.1: Platinum Chemotherapy and Cancer; 3.1.2: Palette of Current Platinum Chemotherapeutic Drugs; 3.1.3: Early History of Cisplatin and Approved Platinum Drugs for the Clinic; 3.2: Mechanism of Action of Cisplatin; 3.2.1: Cisplatin Accumulation; 3.2.2: Cisplatin Activation; 3.2.2.1: Binding to DNA Targets 3.2.2.2: Binding to Non-DNA Targets3.2.3: Cellular Processing of Platinum-DNA Adducts; 3.2.3.1: Cytotoxicity Associated with High Mobility Group (HMG) Proteins; 3.2.3.2: Cytotoxicity Associated with Non-HMG Proteins; 3.3: Limitations of Current Platinum-Based Compounds: New Strategies; 3.4: Novel Concepts in the Development of Platinum Antitumor Drugs; 3.4.1: Functionalized Single-Walled Carbon Nanotubes (SWNTs) as Vehicles for Delivery of Pt(IV)-Prodrugs; 3.4.2: Targeted Nanoparticles for Delivery of Cisplatin for Prostate Cancer 3.4.3: Gold Nanoparticles as Delivery Vehicles for Platinum Compounds |
| Record Nr. | UNINA-9910676604103321 |
| Weinheim, Germany, : bWiley-VCH, c2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Clay Minerals : Their Antimicrobial and Antitoxic Applications / / by Bhaskar Ghosh, Dola Chakraborty
| Clay Minerals : Their Antimicrobial and Antitoxic Applications / / by Bhaskar Ghosh, Dola Chakraborty |
| Autore | Ghosh Bhaskar |
| Edizione | [1st ed. 2023.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2023 |
| Descrizione fisica | 1 online resource (182 pages) |
| Disciplina | 615.2 |
| Soggetto topico |
Mineralogy
Medical sciences Health Sciences |
| ISBN | 3-031-22327-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | An Overview of the Clay Minerals: Composition, Classification, Internal Structure and Properties -- Clay-induced Antimicrobial and Antitoxic Mechanisms: How do the Clays Protect Us From Pathogens and Toxins? -- Traditional Applications of the Antimicrobial and Antitoxic Properties of Clay Minerals -- Antimicrobial Applications of Clays and Their Derivatives in Protection of Human Health -- Antitoxic Applications of Clays in the Protection of Human Health -- Clays in the Global War Against COVID-19: Why are They Preferable Over the Conventional Weaponry? -- The Present and the Future: Advantages, Drawbacks, and Future Prospects of Clays for Protection of Human Health. |
| Record Nr. | UNINA-9910683344303321 |
Ghosh Bhaskar
|
||
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2023 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
El extraordinario poder curativo de la arcilla / / Pierre Bourgeois
| El extraordinario poder curativo de la arcilla / / Pierre Bourgeois |
| Autore | Bourgeois Pierre |
| Pubbl/distr/stampa | [Barcelona, Spain] : , : Editorial De Vecchi, , 2016 |
| Descrizione fisica | 1 online resource (56 pages) |
| Disciplina | 615.2 |
| Soggetto topico | Clay - Therapeutic use |
| Soggetto genere / forma | Electronic books. |
| ISBN | 1-68325-126-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | spa |
| Record Nr. | UNINA-9910466022503321 |
|
Bourgeois Pierre
|
||
| [Barcelona, Spain] : , : Editorial De Vecchi, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
El extraordinario poder curativo de la arcilla / / Pierre Bourgeois
| El extraordinario poder curativo de la arcilla / / Pierre Bourgeois |
| Autore | Bourgeois Pierre |
| Pubbl/distr/stampa | [Barcelona, Spain] : , : Editorial De Vecchi, , 2016 |
| Descrizione fisica | 1 online resource (56 pages) |
| Disciplina | 615.2 |
| Soggetto topico | Clay - Therapeutic use |
| ISBN | 1-68325-126-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | spa |
| Record Nr. | UNINA-9910798520303321 |
|
Bourgeois Pierre
|
||
| [Barcelona, Spain] : , : Editorial De Vecchi, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
El extraordinario poder curativo de la arcilla / / Pierre Bourgeois
| El extraordinario poder curativo de la arcilla / / Pierre Bourgeois |
| Autore | Bourgeois Pierre |
| Pubbl/distr/stampa | [Barcelona, Spain] : , : Editorial De Vecchi, , 2016 |
| Descrizione fisica | 1 online resource (56 pages) |
| Disciplina | 615.2 |
| Soggetto topico | Clay - Therapeutic use |
| ISBN | 1-68325-126-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | spa |
| Record Nr. | UNINA-9910813238603321 |
|
Bourgeois Pierre
|
||
| [Barcelona, Spain] : , : Editorial De Vecchi, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||